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Introduction
 In developing countries, clinical and epidemiological 
studies have shown that Human Papilloma virus (HPV) 
play a main role in the development of different types 
of cervical lesions, and are therefore considered as 
the major infectious agent of genital lesions as well as 
cancers (Ciarrocca et al., 2013). Papillomavirus with 
circular double-stranded DNA genome are small non-
enveloped viruses with 52 to 55 nm diameter. The length 
of their genomes is approximately 800 bp and located in 
icosahedral capsid. Its head is composed of 72 capsomers 
(Best et al., 2012). The head is formed by two structural 
proteins L1 and L2. The L1 viral protein makes up about 
80% of the total viral proteins.HPV virions are related to 
receptors such as alpha-integrins and Laminin which are 
leading HPV to enter in to basal epithelial cells (Norman 
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Abstract
 The human papilloma virus (HPV) causes skin and mucous membrane infections. It crosses from one person 
to another by skin-to-skin contact, such as sexual contact. There are more than 100 types of HPV that can 
influence different parts of the body. Some types of HPV can cause cancer (such as cervical or anal cancer) and 
others can cause warts (such as genital or plantar warts). HPV infection is one of the most common sexually 
transmitted infections (STIs) in Iran and around the world. Considerable molecular evidence suggests a role for 
human papilloma virus (HPV) in the pathogenesis of carcinoma. Epidemiological studies on human papilloma 
viruses (HPVs) infections in general population are critical for the performing of health policy guidelines for 
developing the strategies to hinder the primary and secondary different cancer. In different parts of Iran, there 
is a lack of population-based studies to determine the prevalence of HPV in the general population. The aim of 
this population-based study was therefore to report the prevalence ratse of HPV types among Iranian patients. 
To study the risk of human papilloma virus (HPV) infection, we managed a retrospective study in Kerman 
province, southeast of Iran. For this purpose, 410 patients tested for the presence of HPV DNA using PCR and 
INNo- Lipa assays. HPV DNA was detected in 108 out of 410 patients (26.34%), while it was not detected in any 
of the control group samples. Patients included 23 (21.1%) males and 86 (78.8%) females. HPV type 6 was the 
most common (49%) followed by HPV type 16 (10.1%), and also HPV type11 (9.2%). The prevalence of HPV in 
Iran is comparable to those reported in other regions of the world. In a similar manner, it seems that HPV types 
6, 16 and11 are the most common types in Kerman. Additional studies on larger group of patients, particularly 
in those with pre-invasive forms of disease, are needed to explain the roles of different HPV types in this location 
of Iran.
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et al., 2013). It is thought that viral oncogenes E6 and E7 
alter cell cycle to remain host keratinocytes differentiated 
in a state which is suitable for viral genome replication 
and consequently late gene will be expressed. HPV 
makes tumors such as warts and Papilloma in its natural 
hosts (Mohabatkar, 2007). The Lesion may be cutaneous, 
mucosal squamous epithelium in the larynx, in esophagus 
or genitals. Infection often produced lesions which are 
very small and sometimes not even visible with the naked 
eye (Alsaad et al., 2012). Suppression of immune system 
in humans and animals causes activation of latent infection 
or increases the possibility of virus inoculation from active 
lesions to form bigger lesions (Palefsky., 2006). As a new 
type of virus is considered when its complete genome 
sequence be cloned and its L-ORF DNA be different 
more than 10% with the nearest type of HPV virus. The 
difference between 2-10% type (Subtype) and less than 
Reza Malekpour Afshar et al
Asian Pacific Journal of Cancer Prevention, Vol 14, 20135288
2% a variant (Variant) are measured. Approximately 
140 HPV types have been identified so far. Some types 
of HPV can make warts or Verrucae which they do not 
cause cancer and other types which cause cancer, they 
do not produce warts(Nirchio et al., 2008). Other types 
have no symptoms and they are harmless. Generally, 
about 30-40 types of HPV are transmitted through sexual 
contact and infected genital areas. Some types of HPV 
are transmitted through sexual intercourse may cause 
genital warts (Babiker et al., 2013). Persistent infection 
with High-risk HPV types opposing of warts may lead to 
Precancerous lesions and invasive cancers. However, most 
infections with these types cannot create disease (Gold et 
al., 2013). Seventy percent of women can get HPV in first 
year and 90% of them get it in 2 years. Pap test is used to 
detect abnormal cells that may lead to cancer progression. 
Although the Pap test for cervical cancer decreased the 
incidence and case fatality in developed countries, 11,000 
cases and 3,900 deaths in 2008 occurred in America 
and this rate in the world is 490,000 cases and 270,000 
deaths (Grace et al., 2011; Huang et al., 2013). Due to 
extensive changes in epidemiological studies of various 
cancers and new information about the prevalence and 
HPV types in different countries and also non-uniform 
prevalence, it is concluded that Iran is one of the countries 
where the incidence of cancer and the HPV prevalence 
is high. Iran, which is creating a fair system for death 
registration, it is predicted that nearly 30 thousand people 
annually die from their cancer. According to the study 
which is done by International Agency for Research on 
Cancer (IARC), the cancer incidence in Iran is located 
in the East Mediterranean, about 140 thousand cases, 
but according to other studies, this figure is estimated 
to be 250-200 thousand patients (Karimi et al., 2009).
In developed countries, 7% of risk factors for cancer are 
related to the infection, while in the developing countries 
like the Eastern Mediterranean countries include 26%. 
According to research, now in western countries 40% of 
cancer cases are preventable and in third world countries 
the possibility of preventing cancer is 70%. Thus, the 
incidence of cancer factors should be considered much 
more serious (Chimeddorj et al., 2008; Aljunid et al., 
2010; Diamantopoulou et al., 2013). The most common 
infectious agents for cancer in Iran are HPV, Hepatitis 
B virus and Hepatitis C virus, and Helicobacter pylori 
infection which are including 85% of adult population. 
Therefore, regarding to incidence and high prevalence of 
HPV in Iran, the prevalence of HPV in patients with risk 
factors as well as common genotypes in patients could 
be documented in the report of the ordinary genotypes 
of HPV in Iran. In the future to prevent this virus as well 
as comprehensive supportive program for cancer control 
and fighting with cancer in the country will be important. 
INNO-LiPA HPV detection/genotyping assay kit could 
be used principally for screening purposes. However, no 
data are currently available on the performance and value 
of the assay in a clinical setting.The purpose of this study 
was to determination HPV genotypes in several specimens 
from Kerman ,Southeast of IRAN using the INNO-LiPA 
HPV detection/genotyping assay. The INNO-LiPA HPV 
detection/genotyping assay is capable of detecting and 
genotyping 25 different HPV types simultaneously and 
has proved to be sensitive, specific, simple, and rapid in 
the assessment of HPV.
Materials and Methods
Study population and samples
 In a retrospective study all samples were collected 
and received from different cities of Iran in Besat clinic 
in Kerman during 2008-2012 and the INNO-LiPA test 
was used to verify the positive result and their specific 
types. Specimens were obtained from 410 Women and 
Men. HPV was confirmed in 108 samples using PCR in 
Center lab. Source of samples were Paraffin embedded 
block, vaginal scrape, genital, biopsy, serum specimens. 
Paraffin embedded blocks were processed using xylen 
for remove of paraffin that possibility of isolating DNA 
for HPV detection assays. This method has received 
approval for clinical use from the U.S. Food and Drug 
Administration .Cytological classification was performed 
by an experienced pathologist.
Specimen preparation
 For isolation of nucleic acid from specimens in first 
step using xylen to remove paraffin from blocks in three 
steps and get rid of it by centrifuge, then add 200 μl of 
tissue lysis buffer and proteinase K for 24 hours at room 
temperature then material was isolated using the Total 
Nucleic Acid isolation kit (Roche Applied Science) 
as described by the manufacturer. Nucleic acid was 
resuspended in a final volume of 100 μl; 10 μl was used 
for PCR analysis.
 After isolation of DNA, samples were tested for the 
presence of HPV by the INNO-LiPA HPV detection/
genotyping assay kit. General detection assays, with a 
broad spectrum of specificity for HPV, are now widely 
used for the detection of HPV in clinical specimens 
although the Hybrid Capture II assay (Digene) is the only 
commercially available HPV screening test on the market. 
The Hybrid Capture II assay for HPV DNA detection is 
a liquid-based hybridization assay capable of detecting 
13 HR HPV genotypes simultaneously. In 2003, a newly 
developed PCR-based technique, the Roche AMPLICOR 
HPV Test, was launched. This test is also capable of 
detecting 13 HR HPV types, with simultaneous assessment 
of the presence of the human β-globin gene as a positive 
control. 
INNO-LiPA HPV detection and genotyping
 A) PCR amplification of HPV DNA: Broad-spectrum 
HPV DNA amplification was performed using a short PCR 
fragment assay (INNO-LiPA HPV detection/genotyping 
assay, SPF10 system version 1, manufactured by Labo 
Biomedical Products bv, Rijswijk, The Netherlands). 
This assay amplifies a 65-bp fragment of the L1 open 
reading frame and allows detection of at least 43 different 
HPV types. The SPF10 PCR was performed with a final 
reaction volume of 50 μl containing 10 μl of the isolated 
DNA sample, 10 mmol/liter Tris-HCl (pH 9.0), 50 mmol/
liter KCl, 2.0 mmol/liter MgCl2, 0.1% Triton X-100, 
0.01% gelatin, 200 μmol/liter of each deoxynucleoside 
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triphosphate, 15 pmol each of the forward and reverse 
primers tagged with biotin at the 5’end, and 1.5 U 
of AmpliTaq Gold (Perkin-Elmer). The mixture was 
incubated for 9 min at 94°C, 40 cycles of 45s at 45°C, 
and 40 cycles of 45s at 72°C, with a final extension of 
5 min at 72°C. Each experiment was performed with 
separate positive and negative PCR controls.The presence 
of HPV DNA was determined by hybridization of SPF10 
amplimers to a mixture of general HPV probes recognizing 
a broad range of HPV genotypes, in a microtiter plate 
format, as described previously.
 B) HPV genotyping by reverse hybridization using 
the INNO-LiPA HPV genotyping system: A poly(dT) 
tail was enzymatically added to the 3’ end of each of 25 
oligonucleotides specific for 25 different types, namely, 
types 6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 
45, 51, 52, 53, 54, 56, 58, 59, 66, 68/73, 70, and 74. The 
tailed probes were applied as horizontal lines to membrane 
strips (manufactured by Labo Biomedical Products bv, 
Rijswijk, The Netherlands). The HPV genotyping assay 
was performed as described previously. Briefly, equal 
volumes (10 μl each) of the biotinylated PCR products 
and denaturation solution (400 mmol/liter NaOH, 10 
mmol/liter EDTA) were mixed in test troughs and 
incubated at room temperature for 5 min, after which 
1 ml of prewarmed (37°C) hybridization solution was 
added, followed by the addition of one strip per trough. 
Hybridization was performed for 1 h at 50±0.5°C in a 
closed water bath with back-and-forth shaking. The strips 
were then washed twice with 1 ml of wash solution at 
room temperature for 20 s and once at 50°C for 30 min. 
Following this stringent washing, strips were rinsed 
twice with 1 ml of a standard rinse solution. Strips were 
then incubated on a rotating platform with an alkaline 
phosphatase-labeled streptavidin conjugate diluted in a 
standard conjugate solution, at 20 to 25°C for 30 min, 
after which strips were washed twice with 1 ml of rinse 
solution and once with standard substrate buffer; color 
development was initiated by the addition of 5-bromo-4-
chloro-3-indolylphosphate and nitroblue tetrazolium to 1 
ml of substrate buffer. After 30 min of incubation at room 
temperature, the color reaction was stopped by aspiration 
of the substrate buffer and addition of distilled water. After 
drying, the strips were visually interpreted using a grid.
Statistical analysis
 Chi square and Fisher’s exact Tests were used to 
analyze the data obtained by SPSS 11.5 software (SPSS 
Inc, Chicago; USA). The differences or association with 
p<0.05 were considered statistically significant.
Results 
 Of 108 samples 86 was female (78.8%), mean of age 
30.44±11.2, the age range was 1-54 years old and 23 was 
Male (21.1%), mean of age 31.7±9.4, the age range was 
3-42 years old (Figure 1). A total samples was enrolled 
to our study, which is divided in biopsy 15.5%, paraffin 
embedded block 2.7%, eye 0.9%, genital 71.6% and 
serum 8.2%. Twenty-two genotypes among samples were 
detected. In six samples HPV genotypes was undetectable. 
The most common HPV types in this study were HPV 
genotype 6 that was in female 35 (32.4%) and male 18 
(16.6%) that source of this samples was genital. According 
to our study results, of 108 patients who were positive 
in human papilloma viruses, based on gender, 82 cases 
(75.9%) female and 26 cases (24%) male were positive 
(Figure 2). From this 108 positive list, 53 cases (49%) were 
positive for HPV-6 and showed that 35 (32.4%) female 
and 18 (16.6%) male were positive. For studying about 
rare types such as HPV-9, 13, 33, 34, 35, 59, 69, 70, 71 
just one time these types were positive and that in all of 
types were female (0.9%) and also from total 10 positive 
cases (9.2%) for HPV-11, we reported 6 (5.5%) female and 
4 (3.7%) male. As we predicted, In HPV-16 we had total 
11 (10.1%) positive with 10 (9.2%) female and 1 (0.9%) 
male, showing this type of HPV is prevalent in women. 
Interestingly, 6 cases were positive (5.5%) for HPV-18 
and from which 5 (4.6%) female and 1 (0.9%) male were 
shown and also total 4 cases (3.7%) of HPV-31, 39, 53 
were positive and all of them were female. Moreover, in 
HPV-32, just 2 positive (1.8%) detected and in which 1 
(0.9%) female and 1 (0.9%) male shown and for HPV-
44, 52 only 3 cases (2.7%) and for HPV-51 only 7 cases 
(6.4%) female were shown but no positive male detected. 
Eventually, from total 9 cases (8.3%) in HPV-66, female 
8 (7.4%) and male 1 (0.9%) reported and for HPV-68 
only 2 cases (1.8%) were positive and all were female. 
Generally, we were not able to detect HPV-9, 13, 33, 34, 
35, 59, 69, 70, 71, 31, 39, 53, 44, 52, 51, 68 types in our 
male population (Figure 3).
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Figure 3. Frequency of HPV Types in Two Gender 
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Discussion
Despite the numerous methods for detecting HPV 
viral infection, we have been used INNO-Lippa in this 
study. The INNO-LiPA HPV genotyping assay is capable 
of detecting and genotyping 25 different HPV types at 
the same time and has proven to be sensitive, specific, 
simple, and rapid in the determination of HPV (Chinchai 
et al., 2011; Barbieri et al., 2012). Detection of HPV 
is dependent on the methods employed it cannot be 
cultured in vitro and serological assays lack sensitivity 
and specificity. Therefore detection is entirely based on 
molecular methods such as the INNO-LiPA HPV (Didelot-
Rousseau et al., 2006).
In many developed countries and some developing 
countries many researches in this field have been done. 
In all these studies which have been done by different 
molecular techniques such as PCR and In situ hybridization 
been used, HPV as the main cause of cervical cancer is 
introduced. Papillomavirus (HPV) type 16 and type 18 in 
the first and type 31, 33 and 45 in the second position are 
observed in cancer samples. Some types, like 51, 52 and 54 
in some areas are identified as the cause of cervical cancer. 
(2, 3, 4, 5, 9, 17, 18, 28, ... and 116) (Galan-Sanchez et 
al., 2011; Micalessi et al., 2013).
In a research on samples of cervical cancer have been 
conducted in Croatia, in 61.1% of samples HPV DNA has 
been detected and the most common types in this study 
were HPV-16, HPV-18, HPV-31 and HPV-33 respectively. 
The samples with Dysplasia, HPV-6 and HPV-11 have 
been identified. The few reported cases with more than one 
type of papillomavirus (HPV) are observed in this study 
(Grce et al., 2007). A case-control study in Philippines, 
from all samples, 93/8% of cervical cancers was HPV 
DNA positive while in the control group only 9.2% of the 
cases have HPV genome (Young et al., 2010). In Thailand, 
100 samples with cervical cancer were analyzed by PCR 
and in 82% of cases HPV has been detected. In this study, 
type 16 (42%), type 18 (21%) and type 33 (4%) have been 
identified (Chinchai et al., 2011). 
In a study on patients with invasive cervical cancer 
which have been conducted in Russia, HPV DNA has 
been detected in all cases. The prevalence of different 
HPV types were HPV-16 (64/8%), HPV-18 (10/7%) and 
HPV-45 (8/2%) respectively. However 3/8% of cases has 
not been determined by this method (Samoylova et al., 
1995). In 2012 another study was done in Iran and cervical 
specimens were obtained from women aged 18-59 years 
and from locally diagnosed invasive cervical cancers 
(ICC). HPV was detected and genotyped using PCR-
based assay. HPV prevalence in the general population 
was 7.8% (95% confidence interval: 6.0-9.8) (5.1% of 
high-risk types), with no significant variation by age. 
HPV16/18 accounted for 30 and 82.2% of HPV-positive 
women in the general population and ICC, respectively 
(Zandi et al., 2010).
In an investigation in IRAN in 2012, the prevalence 
of HPV DNA Infection in Patients with Esophageal 
Squamous Cell Carcinoma from the Caspian Sea Area was 
28.3% of upper, 29% of middle and 25.8% of lower third 
of ESCC samples were positive for HPV DNA. 13.6% 
for males and 14.1% for females were HPV positive in 
all samples. In other study on same samples, positive 
specimens were evaluated by Real-time PCR to determine 
HPV genotypes. From the 49 HPV positive cases, of 
ESCC patients, 5 (23.1%), 11 (55 %) and 9 (56.3%) 
of upper, middle and lower third of ESCC specimens, 
respectively were positive by at least one high and one 
low-risk HPV genotypes (Yahyapour et al., 2012). In 
the same study in Iran in 2012, the prevalence of high-
risk human papillomavirus Types 16 and 18 in cervical 
samples from healthy women with normal Pap smears was 
tested by polymerase chain reaction. The prevalence of 
positive HPV findings was 5.5%; high-risk HPV human 
papillomavirus Type 16 prevalence was 2% and no HPV-
18 was reported. The prevalence of HPV was 4.5% in 
younger age group and gradually increased to 20% in next 
decade (Zandi et al., 2010; Shahramian et al., 2011). For 
HPV genotyping in Iran in 2011, patients with cervical 
neoplastic and invasive carcinomas were examined by 
real-time PCR and subsequently PCR products were 
sequenced. The overall genotyping results of phylogenetic 
analysis and hybridization methods were as follows: HPV 
16: 75%; HPV 18: 3%; HPV 31: 1%; HPV 45: 1%. High 
frequency of HPV 16 and low frequency of HPV 18 
were found (Jaberipour et al., 2011). In our study of 410 
patients that referred to Cancer center lab, 108 patients 
were positive for HPV DNA, this test was performed using 
Conventional PCR in center lab, that prevalence of HPV 
in Kerman province was 26.3%. in compared with other 
study in Iran, in a study in 2013, the prevalence of HPV 
infection was 76% in cervical cancer patients and 7% 
among healthy Iranian women. Of the HPV types isolated, 
HPV 16 (54%), 18 (14%), and 31 (6%) were the most 
commonly detected in Iranian cervical cancer patients. 
In an investigation in Shiraz in 2010, the prevalence of 
positive HPV findings was 5.5%; high-risk HPV Type 16 
prevalence was 2% and no patient harbored HPV-18. The 
prevalence of HPV was 4.5% in younger age group and 
gradually increased to 20% in the 4th decade (Safaei et 
al., 2010). According to our study results, of 108 patients 
who were positive in human papilloma viruses, based on 
gender, 82 cases (75.9%) female and 26 cases (24%) male 
were positive. From this 108 positive list, 53 cases (49%) 
were positive for HPV-6 and showed that 35 (32.4%) 
female and 18 (16.6%) male were positive. The most 
common HPV types in this study were HPV genotype 6 
that was in female 35 (32.4%) and male 18 (16.6%) that 
source of this samples was genital. We recommended the 
researchers do further studies on the prevalence of HPV 
infection in Kerman and to inform people of different 
ways to expand it. In addition to periodic examinations 
and Pap smears for women to be given the necessary 
recommendations.
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